Refine by
Hematopoietic Stem Suppliers & Manufacturers
31 companies found
Premium
based inDueren, GERMANY
Since 2005, NIPPON Genetics EUROPE has stood for innovation and quality in biotechnology. In these two decades, we have evolved from a supplier of high quality Japanese technologies to a developer of our own groundbreaking solutions. Our products ...
Enables long term cell storage at -80°C or -196°C. Improved cell recovery and viability after thawing. Ready-to-use freezing media – no programmed or sequential freezing required. Serum-free – no risk of contamination. GMP ...
based inSan Antonio, TEXAS (USA)
StemBioSys is located in San Antonio, Texas and proximate to the University of Texas Health Science Center San Antonio (UTHSC-SA) from which we have licensed proprietary and disruptive technology for the enhanced isolation, growth and delivery of ...
CELLvo™ Matrix is the only commercially available substrate that aims to recapitulate biochemical as well as structural and mechanical cues of the native niche by leaving the extracellular matrix intact. Cell-derived matrices create a ...
based inNoida, INDIA
Advancells is a research-oriented company, focussed on offering authentic, high-quality primary cells including stem cells for research studies, stem cell therapy, preclinical analysis, and even as in vitro tools for clinical research. We wish to be ...
Stroke is mainly characterized by a decreased supply of oxygenated blood to two primary organs of the body, either heart or brain, especially due to blocked and/or ruptured arteries. Specifically, there are three type of Stroke: (a) Ischemic stroke ...
based inAlameda, CALIFORNIA (USA)
Since its inception in 1998, AllCells, a Discovery Life Sciences Company, has focused on advancing science in an innovative, collaborative, and client-centric manner. In our corporate video, AllCells’ Founder, Jay Tong, describes his early days in ...
Mobilized Leukopaks are apheresis products collected from healthy donors treated with FDA-approved drugs to stimulate the migration of CD34+ hematopoietic stem and progenitor cells (HSPCs) from the bone marrow niche ...
based inCambridge, MASSACHUSETTS (USA)
Editas Medicine is a clinical stage genome editing company focused on translating the power and potential of the CRISPR/Cas9 and CRISPR/Cas12a genome editing systems into a robust pipeline of medicines for people living with serious diseases around ...
EDIT-301 is an experimental cell therapy medicine under investigation for the treatment of severe sickle cell disease (SCD) and transfusion-dependent beta thalassemia (TDT). EDIT-301 consists of patient-derived CD34+ hematopoietic ...
based inCambridge, MASSACHUSETTS (USA)
Many of us pursuing work in the biotechnology industry are inspired by a loved one who is living with a disease or the loss of someone in our community. Rare genetic and oncological and immunological diseases not only affect the people living with ...
based inGangnam-gu, SOUTH KOREA
Kangstem Biotech promotes a step-by-step business strategy to optimize its success rate of new global medicine development. Kangstem Biotech will create a world where people can enjoy a healthy and happy life by developing stem cell therapeutic ...
Kangstem Biotech is developing stem cell therapeutic products for patients suffering from rare and incurable diseases using umbilical cord blood-derived stem ...
based inFrederick, MARYLAND (USA)
In 2019, ProMedDx and GLAS Bio were acquired by Precision for Medicine, part of Precision Medicine Group. This new combination significantly bolstered the selection, scientific prowess and solutions available to customers from a single partner. With ...
Advancing your research into hematological malignancies, immunology, and other related areas requires access to high quality human bone marrow mononuclear cells. Precision for Medicine has an extensive inventory of normal, healthy donors with ...
based inCranbury, NEW JERSEY (USA)
Advancing an integrated pipeline of genetic therapies that correct the root cause of complex and rare life-threatening childhood disorders. Our mission is to develop first-in-class and best-in-class, curative gene therapies for patients with ...
LAD-I is a rare genetic disorder affecting the immune system and is caused by a defect in the ITGB2 gene, leading to a deficiency in CD18. Due to this deficiency, white blood cells (primarily neutrophils) are unable to leave the bloodstream to go to ...
based inMelbourne, AUSTRALIA
Mesoblast is using its proprietary mesenchymal lineage cell technology platform to develop and commercialize innovative allogeneic cellular medicines to treat complex inflammatory diseases resistant to conventional standard of care. ...
Mesoblast has a strong and extensive global intellectual property (IP) portfolio with protection extending through to at least 2040 in all major markets. This IP position is expected to provide the Company with substantial commercial advantages as ...
based inGangnam-gu, SOUTH KOREA
MitoImmune Therapeutics Inc. is a drug discovery and development biotech company that harnesses the power of mitochondria and its proprietary technology targeting mitochondria as the source for developing new potential breakthrough therapeutics. Our ...
MIT-001 is an innovative clinical candidate that blocks the root cause of graft-versus-host disease, which often occurs during allogenic hematopoietic stem cell transplantation (HSCT), through a mechanism of action ...
based inJena, GERMANY
We develop, manufacture and sell high-quality automated solutions for life sciences in a broad range of areas including molecular diagnostics, cancer and stem cell research, cell line development and bioprocessing. Our core competencies are in ...
The semi-solid media module was specifically developed for the isolation of bacteria and cell colonies as well as 3D clones from semi-solid and solid media (e.g. methylcellulose, matrigel, ...
based inChangning District, CHINA
Antengene Corporation Limited (“Antengene”, SEHK: 6996.HK) is a leading commercial-stage R&D-driven global biopharmaceutical company focused on the discovery, development, manufacturing and commercialization of innovative ...
Diffuse large B-cell lymphoma (DLBCL) is one of the most common types of non-Hodgkin lymphoma (NHL) in adults and a highly heterogeneous malignancy in both clinical manifestations and prognosis. DLBCL accounts for 30%-40% of all NHL cases, and over ...
based inGrove City, OHIO (USA)
Forge is developing innovative gene therapies that aim to help patients suffering from devastating rare diseases. Forge is building capacity to directly address the growing demand for gene therapy manufacturing. Forge is currently building the ...
Krabbe disease is a devastating neurodegenerative disease affecting about 1 -2.5 in 100,000 people in the U.S. and is inherited in an autosomal recessive manner. Krabbe disease is caused by loss-of-function mutations in the galactosylceramidase ...
based inVirum, DENMARK
Immudex was created in 2009 when it spun off from the diagnostic company Dako, now Agilent. Since then, Immudex has grown in numbers, employees, patents, product lines, partnerships, and customers served. Research, development, and commercial ...
based inRotkreuz, SWITZERLAND
Roche Diagnostics is a division of Roche. We develop and integrate diagnostic solutions that address the challenges of today and anticipate the needs of tomorrow. In more than 100 countries, we offer the industry’s most comprehensive in vitro ...
Immunoassays for the qualitative detection of specific antibodies to Epstein-Barr virus (EBV). The Elecsys EBV panel consists of three immunoassaysto detect antibodies specific to the Epstein-Barr virus (EBV). The three assays, Elecsys EBV IgM, ...
based inSugar Land, TEXAS (USA)
Our mission is to develop and deliver adult stem cell solutions that are safe, effective and affordable for incurable conditions. Our vision is a world where stem cells are regularly used to not only treat disease but prevent it. Today, medicine is ...
The truth is that almost everyone that has banked their newborn's stem cells has banked for the purpose of banking rather than for the purpose of using. According to the American Society for Blood and Marrow Transplantation (ASBMT), the chance of a ...
based inFlorham Park, NEW JERSEY (USA)
Celularity, headquartered in Florham Park, N.J., is a clinical stage biotechnology company leading the next evolution in cellular medicine by delivering off-the-shelf allogeneic placenta-derived cellular therapies at unparalleled scale, quality and ...
We are developing CYNK-101 as a combination treatment for multiple cancer indications. CYNK-101 is manufactured from a specific type of immune cell, NK cells, that we extract from postpartum placentas and then genetically engineer to increase cell ...
based inAllendale, NEW JERSEY (USA)
We are a leading global contract development and manufacturing organization (CDMO) dedicated to the advancement and manufacturing of gene and cell therapy products. Minaris Regenerative Medicine is a leading global contract development and ...
At Minaris Regenerative Medicine, we are committed to bringing together and further developing highly talented, skilled, and dedicated experts with varied backgrounds applicable to gene and cell therapy manufacturing and development. Having this ...
based inMilano, ITALY
We are a clinical-stage biotechnology company pioneering the treatment of cancers with a technology platform that allows the direct delivery of immunotherapeutic payloads within the tumor microenvironment. Intrinsic resistance significantly reduces ...
Temferon™ is a lenti-virus based hematopoietic stem progenitor cell immuno-gene therapy enabling controlled and targeted interferon-α expression within cancers. Biologically delivered via engineered ...